COVID-19's hidden impact on blood clot recovery revealed

NCT ID NCT04465656

Completed Knowledge-focused Sponsor: Hospital St. Joseph, Marseille, France Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tracked 88 adults diagnosed with pulmonary embolism (a serious blood clot in the lungs) during April 2020, the peak of the COVID-19 pandemic in France. Researchers compared complications like recurrence of clots, lung scarring, and death over 6 to 12 months between patients who had COVID-19 and those who did not. The goal was to understand how the virus affects recovery, using serology tests to confirm past infection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could clarify how COVID-19 affects recovery from pulmonary embolism, guiding future treatment.
What could go wrong: This is an observational registry with only 88 participants, so findings may not apply broadly. It does not test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY EMBOLISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary embolism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY EMBOLISM

Contacts and locations

Locations

Hôpital Saint Joseph Marseille

Marseille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.